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807-l The Long-Term Outcome of Patients With Hypertrophic 
Cardiomyopathy and Coronary Artery Disease 
Paul Soraiia, Steve R. Ommen. Rick A. Nishimura, Robert B. McCully. A. Jamil Tajik. 
Bernard J. Gersh, Mayo Clinic and Mayo Foundation. Rochester, MN 
Background. Hypertrophlc cardiomyopathy (HCM) and coronary artery disease (CAD) 
both confer an increased risk of sudden and other cardiac death However, there is a 
paucity of data on the long-term outcomes of patients with HCM who have acquired 
CAD. 
Methods and Results. We examined 475 patients with HCM who underwent coronaly 
angiography at the Mayo Clinic. Patients who were aged ~55 years, had a prior history of 
surgical revascularization. or had abnormal systolic function (left ventricular ejection frac- 
tion or EFc50%) were excluded, leawng a final study population of 299 patients (median 
age, 70 yrs; 131 men). CAD (i.e., luminal stenosis of 50% or more in left main artery or 
70% or more in other epicardial branches) was present in 95 patients. Of the HCM 
patients with CAD, revascularization was undertaken with coronary artery bypass graft- 
ing in 21 and percutaneous coronary intervention in eight. There were no significant dif- 
ferences between HCM patients with CAD and those wIthout CAD with respect to age. 
EF, functtonal class, or prior medical history. In the entlre study population (n=299), there 
were 85 deaths during a mean follow-up of 5.0 yrs. Fifty-seven deaths were cardiac in 
origin, lncludlng 22 sudden cardiac deaths. In comparison to HCM patients without CAD, 
those with concomitant disease demonstrated markedly reduced survival. For HCM 
patients with CAD and those without CAD, ten-year survival free of all-cause mortality 
was 43.3% (95% Cl, 30.4 to 56.1%) and 69.9% (61.8 to 78%), respectively (p=O.O003, 
log-rank). For the endpoint of cardiac death, this survival was 59.1% (45.6 to 72.5%) vs. 
78.2% (70.7 to 85.8%) (p=O.O05). For the endpoint of sudden death, this survival was 
78.3% (66.4 to 90.3%) vs. 91.7% (86.2 to 97.1%) (p=O.Ol). The presence of CAD also 
was predictive of these events in multivariate models that additionally identified prior 
stroke and atrial fibrillation as co-variates with statistical significance (pcO.05). 
Conclusions Patients with HCM who have acquired CAD are at markedly Increased 
r!sk of sudden death. other causes of cardiac death, and overall mortality. 
9:30 a.m. 
807-2 Prevalence, Spectrum, and Phenotype of Beta Myosin 
Heavy Chain Mutations in Patients With Hypertrophic 
Cardiomyopathy 
Michele A. Jaeger, Sara L. Van Driest, Melissa L. Will, Bernard J. Gersh. Steve R. 
Ommen, Michael J. Ackerman, Mayo Clmic, Rochester, MN 
Background: Beta myosin heavy chain (MYH7) mutations are reportedly pathogenic in 
25.30% of cases of Hypertrophic Cardiomyopathy (HCM). Approximately IO specific 
mutations have been designated as either “malignant” or “benign.” However, the fre- 
quency, spectrum, and phenotype of MYH7 mutations in a single large cohori are 
unknown. We analyzed such a cohort of HCM patients for mutations in MYH7and deter- 
mined the genotype-phenotype correlations for this subset. 
Methods: DNA from 395 unrelated HCM patients was obtained and analyzed. Mutational 
analysis of all 38 protein coding exons of MYH7 was performed using polymerase chain 
reaction, denaturing high performance liquid chromatography, and DNA sequencing. 
Clinical data were archived independent of patient genotype. 
Results: Overall, the mean age at diagnosis was 41.2 * 19 years. Over half had left ven- 
tricular outflow tract obstruction. One-third had a family history of HCM and 14% had a 
family history of sudden cardiac death. In all, 54 patients (14%) were identified with 
MYH7 mutations. Thirty-eight different mutations were identified including 24 (63%) pre- 
viously unpublished, novel mutations. When compared to the remaining cohort of HCM 
patients without a MYH7mutatlon. patients with MYH7 mutations were younger at diag- 
nosis (33.1 * 18 vs 41.3 f 19 years, p = 0.0004), were more likely to have a first degree 
relative with HCM (40% vs 31%, p = 0.009), had greater left ventricular wall thickness 
(24.3 * 8 vs 21.5 * 6 mm, p= 0.0007), and received a myectomy more frequently (59% 
vs 41%, p = 0.004). However, there was no difference in frequency of sudden death 
(3.7% vs 2.9% p = NS). 
Conclusions: This study represents a comprehensive mutational analysis of the MYH7 
gene in a large cohort from a single tertiary referral center for HCM. The profound genetic 
heterogeneity is underscored as nearly two-thirds of the mutations discovered were 
novel. Here. MYH7 mutations accounted for less than 15% of HCM. Interestinalv. _, 
patients with MYH7-HCM had an earlier diagnosis, more family history of HCM, more 
hypertrophy, and more need for myectomy than patients with non- MYH7-HCM. However, 
these patients did not experience more sudden cardiac death. 
807-3 Prognosis of Patients With Hypertrophic Obstructive 
Cardiomyopathy After Transcoronary Ablation of Septal 
Hypertrophy 
Thorsten Lawrenz, Frank Lieder, Frank Gietzen, Udo Goetsch, Horst Kuhn, Bielefeld 
Klinikum, Bielefeld, Germany 
Background and Methods: Transcoranary Ablation of Septal Hypertrophy (TASH) con- 
stitutes a new catheter based therapeutic option for symptomatic patients with hyper- 
trophic obstructive cardiomyopathy (HOCM). Regarding the prognosis after TASH only 
few data are available. Based on a validated quality of life questionnaire (QoL) and serial 
control examinations we analysed the clinkxl course of all patients treated in our Institu- 
tion up to December 2001. 
Results: Since 1995 329 pts were treated by TASH in our institution (pressureiangiogra- 
phy guided technique, age 60.0 * 13.1 years, male/female (1551174 pts), 98.8% follow 
up (325/329 pts), mean follow up time 2.1 f 1.6 years, maximum 6.2 years, Kaplan-Meier 
calculations). The TASH related total in hospital mortality amounts to 1.8% (6/329pts). 
Sudden out of hospital death occurred in 4 pts and not sudden, not TASH related death 
in 19 pts (Table). An ethanol amount of more than 2.0 ml was an independent predictor 
of an increased risk for cardiac death (p = 0.047, Cox regression analysis), without a sig- 
nificant difference in the &L-benefit rate (s 2.0 ml vs. > 2.0 ml ethanol). Advanced age 
(> 61 years) was another independent predictor of increased prognostic risk (p = 0.002) 
Cause of Death in 329 pts After TASH (98.8% Follow up) 
HOCM-related 
TASH-related in hospital death 
Sudden cardiac death during follow up 
HOCM-related death with respect to the amount of ethanol 
injected 
Low ethanol subset (< 2.0 ml) 
High ethanol subset (> 2.0 ml) 
Not HOCM-, not TASH-related death (e.g. carcinoma) 
Total in hospital mortality 
Total in hospital mortality (pts without severe comorbidity) 
Total annual mortality 
Annual cardiac mortality (pts with sudden death) 
Annual cardiac mortality after hospital discharge 
Death (pts) 
10 
6 
4 
IO 
2 
8 
19 
1.8% 
0.3% 
4.3% per year 
1.5% per year 
0.6% per year 
Conclusions: For the first time annual mortality rates after TASH are communicated. 
The prognosis compares favourable with the good prognosis after surgery for HOCM. It 
turned out lo be significantly better in pts treated with small amounts of ethanol (without 
reduction of clinical benefit). 
lo:oo a.m. 
807-4 Upper Limits and Clinical Significance of Left Atrium 
Dilatation in Trained Athletes 
Antonio Pelliccia, Fernando M. Di Paolo, France Culasso, Filippo M. Quattrini, Stefano 
Caselli, Barry J. Maron, lnstltute Sports Science. Rome, Italy, Minneapolis Heart Institute 
Foundation, Minneapolis, MN 
Background Left atrium (LA) dimension may be increased in trained athletes, raising 
the question of differential diagnosis between athlete’s hearl and structural cardiac dis- 
ease. 
Methods We prospectively examined LA transverse dimension by echocardiography, 
and determinants of LA size were assessed in 1,823 competitive athletes (1,298 men), 
aged IO-56 years (mean 24), participating in 38 different sports, with multivariate analy- 
sis. 
Results LA dimension showed a wide range, 23.50 mm (mean 36.8i4.2) in men, and 
20-46 mm (mean 32.0+4.0) in women, and was enlarged (based on arbitrary cllnical cut- 
point of 240 mm) in 362 (20%) subjects (343 male, 19 female), including 38 (2%) with 
markedly dilated LA (245 mm). of these 362, only 9 (2%) showed structural cardiac dis- 
eases potentially responsible for LA enlargement including mitral or aortic valve disease 
with regurgitation in 5, hypertrophic and dilated cardiomyopathy, ischemic heart disease 
and atrial septal defect in I, respectively. Of the remaining 353 athletes with enlarged LA, 
305 (86%) showed increased left ventricular (LV) cavity dimension (-155 mm) andior wall 
thickness (> 13 mm), with normal systolic function and transmitrat diastolic filling paltern. 
compatible with physiologic LV hypertrophy. Stepwise regression analysis showed that 
most of the variability in LA size was explained by LV cavity dimension. wall thickness, 
age and BSA (multiple F? = 0.59). Furthermore, sports such as cycling, rowing rugby and 
ice hockey showed the greatest effect on LA enlargement, Each athlete remained free of 
symptoms and without ventricular dysfunction, over 4+2 years. 
Conclusions In a population of tralned athletes, LA shows a broad range of dimension 
and is increased (i.e. 240 mm) in 20% of subiects. including 2% with marked dilated 1 b . I  
(245 mm) compatible with primary cardiac diskase. In the pr&nce of normal LV systolic 
function and fillina and in the absence of svmptoms or clinical events. left atrial dilatatinn _.. , 
likely represents an extreme physiologic adaptation to intensive athletic conditioning and, 
therefore, another component of the “athlete’s heart”. 
